1
|
Millar B, de Gaetano M. Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. Front Pharmacol 2023; 14:1125858. [PMID: 36865918 PMCID: PMC9971729 DOI: 10.3389/fphar.2023.1125858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Accepted: 01/31/2023] [Indexed: 02/16/2023] Open
Abstract
Atherosclerosis is a progressive, multifactorial inflammatory, and dyslipidaemic disease, responsible for the majority of cardiovascular diseases globally. The chronic inflammation is the main driver of the initiation and progression of such disease, as a result of an imbalanced lipid metabolism and an ineffective immune response to attenuate the inflammatory component. The importance of inflammation resolution is being increasingly recognised in atherosclerosis and cardiovascular disease. It has a complex mechanism consisting of multiple stages, including restoring an effective removal of apoptotic bodies (efferocytosis) and their degradation (effero-metabolism), a macrophage phenotype switching towards resolving phenotypes, and the promotion of tissue healing and regeneration. The low-grade inflammation associated with atherosclerosis development is a driving force in disease exacerbation, and hence inflammation resolution is a key area of research. In this review, we explore the complex disease pathogenesis and its many contributing factors to gain a greater understanding of the disease and identify the current and potential therapeutic targets. First-line treatments and their efficacy will also be discussed in detail, to highlight the emerging field of resolution pharmacology. Despite the great efforts made by current gold-standard treatments, such as lipid-lowering and glucose-lowering drugs, they remain ineffective at tackling residual inflammatory risk and residual cholesterol risk. Resolution pharmacology represents a new era of atherosclerosis therapy, as endogenous ligands associated with inflammation resolution are exploited for their pharmacological benefits in a more potent and longer-acting manner. Novel FPR2-agonists, such as synthetic lipoxin analogues, provide an exciting new approach to enhance the pro-resolving response of the immune system and subsequently end the pro-inflammatory response to allow for an anti-inflammatory and pro-resolving environment for tissue healing, regeneration, and return to homeostasis.
Collapse
Affiliation(s)
- Braden Millar
- Diabetes Complications Research Centre, Conway Institute & School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
| | | |
Collapse
|
2
|
Cao Q, Zhao J, Xing M, Xiao H, Zhang Q, Liang H, Ji A, Song S. Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances. Mar Drugs 2020; 18:md18090440. [PMID: 32854344 PMCID: PMC7551282 DOI: 10.3390/md18090440] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 08/19/2020] [Accepted: 08/20/2020] [Indexed: 12/18/2022] Open
Abstract
Atherosclerosis is a chronic disease characterized by lipid accumulation and chronic inflammation of the arterial wall, which is the pathological basis for coronary heart disease, cerebrovascular disease and thromboembolic disease. Currently, there is a lack of low-cost therapeutic agents that effectively slow the progression of atherosclerosis. Therefore, the development of new drugs is urgently needed. The research and development of marine-derived drugs have gained increasing interest from researchers across the world. Many marine organisms provide a rich material basis for the development of atherosclerotic drugs. This review focuses on the latest technological advances in the structures and mechanisms of action of marine-derived anti-atherosclerotic substances and the challenges of the application of these substances including marine polysaccharides, proteins and peptides, polyunsaturated fatty acids and small molecule compounds. Here, we describe the theoretical basis of marine biological resources in the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Qi Cao
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Jiarui Zhao
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Maochen Xing
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Han Xiao
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Qian Zhang
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Hao Liang
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
| | - Aiguo Ji
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
- School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
- Correspondence: (A.J.); (S.S.)
| | - Shuliang Song
- Marine College, Shandong University, Weihai 264209, China; (Q.C.); (J.Z.); (M.X.); (H.X.); (Q.Z.); (H.L.)
- Correspondence: (A.J.); (S.S.)
| |
Collapse
|
3
|
Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu). Pharmacol Res 2019; 141:541-550. [DOI: 10.1016/j.phrs.2018.12.019] [Citation(s) in RCA: 65] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 12/18/2018] [Accepted: 12/20/2018] [Indexed: 12/20/2022]
|
4
|
Emerging role of various signaling pathways in the pathogenesis and therapeutics of atherosclerosis. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.rvm.2017.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
5
|
Mohamad H, Rosmiati, Muhammad TST, Andriani Y, Bakar K, Ismail N, Saidin J, Latip J, Musa N, Parenrengi A. Potential Secondary Metabolites from Marine Sponge Aaptos aaptosfor Atherosclerosis and Vibriosis Treatments. Nat Prod Commun 2017. [DOI: 10.1177/1934578x1701200819] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Natural products play a crucial role in drug discovery. In the last decade, the advent of marine natural product research has produced a remarkable number of compounds, particularly those isolated from marine sponges, with a broad range of activities for the treatment of human and animal diseases. In this study, five known alkaloids namely aaptamine (1), 9-demethylaaptamine (2), 4- N-methylaaptamine (3), 9-methoxyaaptamine (4), 9-demethyloxyaaptamine (5), an uncommon amide in sponge, 4-hydroxybenzamide (6) and 3 β,5α-cholesterol (7) were isolated from the butanol extract of Aaptos aaptos (Schmidt, 1864) by bioactivity-guided isolation. Their structures were determined based on a detailed analysis of their 1D and 2D spectroscopic NMR and EIMS spectral data as well as comparison with literature data. Cytotoxic activity and anti-atherosclerotic property of the compounds were determined based on their ability to increase the transcriptional activity of SRB1 promoter and PPRE in human liver HepG2 cell line. The results showed that compounds 4 and 7 exhibited cytotoxic effects and compounds 1–4 and 7 increased the transcriptional activity of SRB1 promoter and PPRE. This suggests that compounds isolated from A. aaptos may have potential as anti-cancer agents and to reduce the progression of atherosclerosis. In addition, the compounds 1–4 displayed antibacterial activity against shrimp pathogenic bacteria, Vibrio harveyi and Vibrio sp. This suggests that the compounds have potential as vibriosis treatment.
Collapse
Affiliation(s)
- Habsah Mohamad
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Rosmiati
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
- Research Institute for Coastal Aquaculture (RICA) Jl. Makmur Dg. Sitakka No. 129 Maros 90512. Indonesia
| | | | - Yosie Andriani
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Kamariah Bakar
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Noraznawati Ismail
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Jasnizat Saidin
- Institute of Marine Biotechnology, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
- School of Marine & Environmental Sciences, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Jalifah Latip
- School of Chemical Sciences and Food Technology, Faculty of Science & Technology, Universiti Kebangsaan Malaysia, Bangi, 43600 Selangor Darul Ehsan, Malaysia
| | - Najiah Musa
- School of Fisheries Sciences and Aquaculture, University Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia
| | - Andi Parenrengi
- Research Institute for Coastal Aquaculture (RICA) Jl. Makmur Dg. Sitakka No. 129 Maros 90512. Indonesia
| |
Collapse
|
6
|
Chen MH, Wu YX, Xu YN, Liu P, Yu LY, Hong B, Jiang W, Si SY. A new trichostatin analog from Streptomyces sp. CPCC 203909. JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 2015; 17:676-682. [PMID: 25977996 DOI: 10.1080/10286020.2015.1042372] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A new trichostatin analog (1) and two known analogs (2, 3) have been isolated from the rice fermentation of the Streptomyces sp. CPCC 203909. Their structures were determined by spectroscopic and chemical methods. The absolute configurations of 1 were assigned by Marfey's method, combined with comparing the NMR and circular dichroism spectroscopic data of 2 and 3. Compound 1 showed cytotoxicity against human embryonic kidney 293 cell line with IC50 value of 39.2 μM.
Collapse
Affiliation(s)
- Ming-Hua Chen
- a Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100050 , China
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Andriani Y, Tengku-Muhammad TS, Mohamad H, Saidin J, Syamsumir DF, Chew GS, Abdul Wahid ME. Phaleria macrocarpa Boerl. (Thymelaeaceae) leaves increase SR-BI expression and reduce cholesterol levels in rats fed a high cholesterol diet. Molecules 2015; 20:4410-29. [PMID: 25759957 PMCID: PMC6272643 DOI: 10.3390/molecules20034410] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Revised: 12/23/2014] [Accepted: 01/13/2015] [Indexed: 11/16/2022] Open
Abstract
In vitro and in vivo studies of the activity of Phaleria macrocarpa Boerl (Thymelaeaceae) leaves against the therapeutic target for hypercholesterolemia were done using the HDL receptor (SR-BI) and hypercholesterolemia-induced Sprague Dawley rats. The in vitro study showed that the active fraction (CF6) obtained from the ethyl acetate extract (EMD) and its component 2',6',4-trihydroxy-4'-methoxybenzophenone increased the SR-BI expression by 95% and 60%, respectively. The in vivo study has proven the effect of EMD at 0.5 g/kgbw dosage in reducing the total cholesterol level by 224.9% and increasing the HDL cholesterol level by 157% compared to the cholesterol group. In the toxicity study, serum glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) activity were observed to be at normal levels. The liver histology also proved no toxicity and abnormalities in any of the treatment groups, so it can be categorized as non-toxic to the rat liver. The findings taken together show that P. macrocarpa leaves are safe and suitable as an alternative control and prevention treatment for hypercholesterolemia in Sprague Dawley rats.
Collapse
Affiliation(s)
- Yosie Andriani
- Institute of Marine Biotechnology, University of Malaysia Terengganu, Kuala Terengganu 21030, Terengganu, Malaysia.
- Chemistry Department, Faculty of Mathematics and Natural Sciences, Universitas Bengkulu (UNIB), Bengkulu 38371, Indonesia.
| | | | - Habsah Mohamad
- Institute of Marine Biotechnology, University of Malaysia Terengganu, Kuala Terengganu 21030, Terengganu, Malaysia.
| | - Jasnizat Saidin
- Institute of Marine Biotechnology, University of Malaysia Terengganu, Kuala Terengganu 21030, Terengganu, Malaysia.
| | - Desy Fitrya Syamsumir
- Institute of Marine Biotechnology, University of Malaysia Terengganu, Kuala Terengganu 21030, Terengganu, Malaysia.
| | - Guat-Siew Chew
- Biomedical Science, School of Health Sciences, Federation University, Ballarat 3350, Australia.
| | - Mohd Effendy Abdul Wahid
- Institute of Marine Biotechnology, University of Malaysia Terengganu, Kuala Terengganu 21030, Terengganu, Malaysia.
| |
Collapse
|
8
|
Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2015; 2015:391790. [PMID: 25821554 PMCID: PMC4364374 DOI: 10.1155/2015/391790] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/11/2015] [Accepted: 02/15/2015] [Indexed: 01/07/2023]
Abstract
Cardiorenal Syndrome Type 1 (Type 1) is a specific condition which is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Even though its pathophysiology is complex and not still completely understood, oxidative stress seems to play a pivotal role. In this study, we examined the putative role of oxidative stress in the pathogenesis of CRS Type 1. Twenty-three patients with acute heart failure (AHF) were included in the study. Subsequently, 11 patients who developed AKI due to AHF were classified as CRS Type 1. Quantitative determinations for IL-6, myeloperoxidase (MPO), nitric oxide (NO), copper/zinc superoxide dismutase (Cu/ZnSOD), and endogenous peroxidase activity (EPA) were performed. CRS Type 1 patients displayed significant augmentation in circulating ROS and RNS, as well as expression of IL-6. Quantitative analysis of all oxidative stress markers showed significantly lower oxidative stress levels in controls and AHF compared to CRS Type 1 patients (P < 0.05). This pilot study demonstrates the significantly heightened presence of dual oxidative stress pathway induction in CRS Type 1 compared to AHF patients. Our findings indicate that oxidative stress is a potential therapeutic target, as it promotes inflammation by ROS/RNS-linked pathogenesis.
Collapse
|
9
|
Chen M, Wu Y, He Y, Xu Y, Li Y, Li D, Feng T, Yu L, Hong B, Jiang W, Si S. Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909. Bioorg Med Chem Lett 2015; 25:562-5. [DOI: 10.1016/j.bmcl.2014.12.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2014] [Revised: 11/07/2014] [Accepted: 12/09/2014] [Indexed: 01/07/2023]
|
10
|
Xu Y, Liu Q, Xu Y, Liu C, Wang X, He X, Zhu N, Liu J, Wu Y, Li Y, Li N, Feng T, Lai F, Zhang M, Hong B, Jiang JD, Si S. Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT. J Lipid Res 2014; 55:1634-47. [PMID: 24908654 DOI: 10.1194/jlr.m044198] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Indexed: 11/20/2022] Open
Abstract
ABCA1 and scavenger receptor class B type I (SR-BI)/CD36 and lysosomal integral membrane protein II analogous 1 (CLA-1) are the key transporter and receptor in reverse cholesterol transport (RCT). Increasing the expression level of ABCA1 and SR-BI/CLA-1 is antiatherogenic. The aim of the study was to find novel antiatherosclerotic agents upregulating expression of ABCA1 and SR-BI/CLA-1 from natural compounds. Using the ABCA1p-LUC and CLA-1p-LUC HepG2 cell lines, we found that rutaecarpine (RUT) triggered promoters of ABCA1 and CLA-1 genes. RUT increased ABCA1 and SR-BI/CLA-1 expression in vitro related to liver X receptor alpha and liver X receptor beta. RUT induced cholesterol efflux in RAW264.7 cells. ApoE-deficient (ApoE(-/-)) mice treated with RUT for 8 weeks showed ∼68.43, 70.23, and 85.56% less en face lesions for RUT (L), RUT (M), and RUT (H) groups, respectively, compared with the model group. Mouse macrophage-specific antibody and filipin staining indicated that RUT attenuated macrophages and cholesterol accumulations in atherosclerotic lesions, respectively. Additionally, ABCA1 and SR-BI expression was highly induced by RUT in livers of ApoE(-/-) mice. Meanwhile, RUT treatment significantly increased the fecal (3)H-cholesterol excretion, which demonstrated that RUT could promote RCT in vivo. RUT was identified to be a candidate that protected ApoE(-/-) mice from developing atherosclerosis through preferentially promoting activities of ABCA1 and SR-BI within RCT.
Collapse
Affiliation(s)
- Yanni Xu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Qi Liu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Yang Xu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Chang Liu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Xiao Wang
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Xiaobo He
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Ningyu Zhu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Jikai Liu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Yexiang Wu
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Yongzhen Li
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Ni Li
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Tingting Feng
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Fangfang Lai
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Murui Zhang
- Sir Runrun Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang Province 310016, China
| | - Bin Hong
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Jian-Dong Jiang
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| | - Shuyi Si
- Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
| |
Collapse
|
11
|
Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents. Molecules 2011; 16:9178-93. [PMID: 22048700 PMCID: PMC6264451 DOI: 10.3390/molecules16119178] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Revised: 10/20/2011] [Accepted: 10/28/2011] [Indexed: 01/29/2023] Open
Abstract
Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) were reported in our recent publication as novel human high density lipoprotein (HDL) receptor CD36 and Lysosomal integral membrane protein-II Analogous-1 (CLA-1) up-regulators. As part of a broader effort to more fully explore the structure-activity relationships (SAR) of CLA-1 up-regulators, we synthesized a series of hydroxamic acid derivatives and evaluated their CLA-1 up-regulating activities in HepG2 cells. Some compounds exhibited over 10-fold up-regulation of CLA-1 expression in HepG2 cells at 10 μg/mL concentration. The compound 1g showed the best potency, with a lower EC50 than TSA (EC50 = 0.32 μM versus 1.2 μM). These compounds provide early new CLA-1 up-regulators with potential for treating atherosclerosis.
Collapse
|
12
|
Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85:596-605. [PMID: 20962076 PMCID: PMC3014195 DOI: 10.1128/jvi.01592-10] [Citation(s) in RCA: 190] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Accepted: 10/04/2010] [Indexed: 12/12/2022] Open
Abstract
Hepatitis C virus (HCV) can initiate infection by cell-free particle and cell-cell contact-dependent transmission. In this study we use a novel infectious coculture system to examine these alternative modes of infection. Cell-to-cell transmission is relatively resistant to anti-HCV glycoprotein monoclonal antibodies and polyclonal immunoglobulin isolated from infected individuals, providing an effective strategy for escaping host humoral immune responses. Chimeric viruses expressing the structural proteins representing the seven major HCV genotypes demonstrate neutralizing antibody-resistant cell-to-cell transmission. HCV entry is a multistep process involving numerous receptors. In this study we demonstrate that, in contrast to earlier reports, CD81 and the tight-junction components claudin-1 and occludin are all essential for both cell-free and cell-to-cell viral transmission. However, scavenger receptor BI (SR-BI) has a more prominent role in cell-to-cell transmission of the virus, with SR-BI-specific antibodies and small-molecule inhibitors showing preferential inhibition of this infection route. These observations highlight the importance of targeting host cell receptors, in particular SR-BI, to control viral infection and spread in the liver.
Collapse
Affiliation(s)
- Claire L. Brimacombe
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Joe Grove
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Luke W. Meredith
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Ke Hu
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Andrew J. Syder
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Maria Victoria Flores
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Jennifer M. Timpe
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Sophie E. Krieger
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Thomas F. Baumert
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Timothy L. Tellinghuisen
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Flossie Wong-Staal
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Peter Balfe
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| | - Jane A. McKeating
- Hepatitis C Research Group, Institute For Biomedical Research, University of Birmingham, Birmingham B15 2TT, United Kingdom, iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, California 92191-0530, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Inserm U748, Université de Strasbourg and Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France, Department of Infectology, The Scripps Research Institute, Jupiter, Florida 33458
| |
Collapse
|
13
|
Yang Y, Wang L, Si S, Hong B. How can high-throughput screening deliver drugs to treat atherosclerosis? Expert Opin Drug Discov 2010; 5:1175-88. [DOI: 10.1517/17460441.2010.529896] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
14
|
Identification of trichostatin A as a novel transcriptional up-regulator of scavenger receptor BI both in HepG2 and RAW 264.7 cells. Atherosclerosis 2009; 204:127-35. [DOI: 10.1016/j.atherosclerosis.2008.08.041] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2008] [Revised: 08/23/2008] [Accepted: 08/26/2008] [Indexed: 12/17/2022]
|
15
|
Yang Y, Jiang W, Wang L, Zhang ZB, Si SY, Hong B. Characterization of the Isoflavone Pratensein as a Novel Transcriptional Up-Regulator of Scavenger Receptor Class B Type I in HepG2 Cells. Biol Pharm Bull 2009; 32:1289-94. [DOI: 10.1248/bpb.32.1289] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Yuan Yang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| | - Wei Jiang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| | - Li Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| | - Zhong-Bing Zhang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| | - Shu-Yi Si
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| | - Bin Hong
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
| |
Collapse
|
16
|
Zhang J, Chu W, Crandall I. Lipoprotein binding preference of CD36 is altered by filipin treatment. Lipids Health Dis 2008; 7:23. [PMID: 18582374 PMCID: PMC2483703 DOI: 10.1186/1476-511x-7-23] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2008] [Accepted: 06/26/2008] [Indexed: 11/30/2022] Open
Abstract
The class B scavenger receptor CD36 binds multiple ligands, including oxidized and native lipoprotein species. CD36 and the related receptor SR-B1 have been localized to caveolae, domains that participate in cell signaling, transcytosis, and regulation of cellular cholesterol homeostasis. Previous work has indicated that the ligand preference of CD36 may depend on the cell type in which it is expressed. To determine if the presence or absence of caveolae is the determining factor for lipoprotein preference, we treated CHO-CD36 and C32 cells with filipin. Filipin treatment rapidly increased the binding capacity of CD36 for the native lipoproteins HDL and LDL, but did not affect the binding capacity of CD36 for oxidized LDL. Filipin treatment affected the distribution of caveolin and CD36 suggesting that the presence caveolae may modulate the ligand preference of CD36. However, its molecular mechanism how CD36 and caveolin interaction in regulating lipoprotein transport remains to be further studied.
Collapse
Affiliation(s)
- Jianshe Zhang
- Department of Bioengineering and Environmental Science, Changsha University, Changsha, Hunan, PR China.
| | | | | |
Collapse
|
17
|
Rodríguez-Sureda V, López-Tejero MD, Llobera M, Peinado-Onsurbe J. Social stress profoundly affects lipid metabolism: Over-expression of SR-BI in liver and changes in lipids and lipases in plasma and tissues of stressed mice. Atherosclerosis 2007; 195:57-65. [PMID: 17222414 DOI: 10.1016/j.atherosclerosis.2006.11.038] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2006] [Revised: 10/27/2006] [Accepted: 11/29/2006] [Indexed: 12/21/2022]
Abstract
We examined the effect of chronic social stress, similar to that endured by humans, on lipid metabolism of mice. The activity of the lipoprotein lipase (LPL) enzyme increased in adrenals, while in plasma it diminished significantly. Hepatic lipase (HL) was strongly affected in liver and adrenal glands, increasing four-fold and three-fold, respectively. At the same time, scavenger receptor class-B type-I (SR-BI), which are considered the high-density lipoprotein (HDL) receptor in the liver, increased significantly. Although the adrenals do not synthesise HL, the increase in HL may facilitate the uptake of HDL cholesterol for the synthesis of corticoids, which increase significantly following chronic stress. The volume of adrenal glands in control animals was significantly higher than in stressed animals (1.23+/-0.12 mm3 versus 0.29+/-0.06 mm3, p<0.001), corresponding with the weight difference of these organs. Medulla volume was also different in the two groups (0.27+/-0.10 mm3 versus 0.04+/-0.02 mm3, p<0.05). Despite this, corticosterone in plasma was significantly higher in stressed animals. Our results shows, for the first time, the effect of chronic social stress on lipid metabolism in general, and in particular on the SR-BI receptor and HL, which is directly involved in cholesterol reverse transport.
Collapse
Affiliation(s)
- Víctor Rodríguez-Sureda
- Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Avda. Diagonal 645, E-08028 Barcelona, Spain
| | | | | | | |
Collapse
|
18
|
Yang Y, Zhang Z, Jiang W, Gao L, Zhao G, Zheng Z, Wang M, Si S, Hong B. Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay. ACTA ACUST UNITED AC 2007; 12:211-9. [PMID: 17259591 DOI: 10.1177/1087057106297568] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Scavenger receptor class B type I (SR-BI) is the high-affinity high-density lipoprotein (HDL) receptor, and CLA-1 is the human homologue of the murine SR-BI. CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis due to its pivotal role in overall HDL cholesterol (HDL-C) metabolism and its antiatherogenic activity in vivo. To search for active compounds that can increase CLA-1 transcription, a novel cell-based assay was developed for application in high-throughput screening (HTS). Human hepatoma HepG2 cells were transfected with a CLA-1-promoter-luciferase reporter gene construct, and the stable transfected cell line was selected and named CLAp-LUC HepG2. With rosiglitazone as a positive control, this stable cell line was used to establish a specific CLA-1 gene expression assay in a 96-well microplate format. The evaluating parameter Z' value of 0.64 showed that this cell-based HTS assay was robust and reliable. Screening of 6000 microbial secondary metabolite crude extracts identified 8 positive strains. Between 2 identified CLA-1 up-regulators produced by actinomycete strain 04-4776, 4776B may stimulate not only the expression of CLA-1 on the transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. The active compounds originated from this HTS assay may be developed to drug candidates or lead compounds for new antiatherosclerosis agents.
Collapse
MESH Headings
- Actinomycetaceae/metabolism
- Biological Assay/methods
- Carbocyanines
- Carcinoma, Hepatocellular/pathology
- Cell Line, Tumor
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical
- Fermentation
- Fluorescent Dyes
- Gene Expression Regulation/drug effects
- Genes, Reporter
- Humans
- Hydroxyl Radical/chemistry
- Isoflavones/isolation & purification
- Isoflavones/pharmacology
- Lipoproteins, HDL/genetics
- Lipoproteins, HDL/metabolism
- Liver Neoplasms/pathology
- Luciferases/metabolism
- PPAR gamma/agonists
- Receptors, Lipoprotein/genetics
- Receptors, Lipoprotein/metabolism
- Recombinant Fusion Proteins/metabolism
- Rosiglitazone
- Scavenger Receptors, Class B/genetics
- Scavenger Receptors, Class B/metabolism
- Thiazolidinediones/pharmacology
- Transcription, Genetic/drug effects
- Up-Regulation
Collapse
Affiliation(s)
- Yuan Yang
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Batetta B, Sanna F. Cholesterol metabolism during cell growth: Which role for the plasma membrane? EUR J LIPID SCI TECH 2006. [DOI: 10.1002/ejlt.200600015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
20
|
Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 2005; 11:954-9. [PMID: 15742395 PMCID: PMC4250784 DOI: 10.3748/wjg.v11.i7.954] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells.
METHODS: Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method.
RESULTS: The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26±5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 µg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 µg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 μg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 μg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells.
CONCLUSION: rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.
Collapse
Affiliation(s)
- Bin Lou
- Department of Biochemistry, School of Pharmacy, Fudan University, Shanghai 200032, China
| | | | | | | | | | | |
Collapse
|
21
|
Marcil M, O'Connell B, Krimbou L, Genest J. High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Rev Cardiovasc Ther 2004; 2:417-30. [PMID: 15151487 DOI: 10.1586/14779072.2.3.417] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The plasma level of high-density lipoprotein (HDL)-cholesterol is inversely correlated with coronary artery disease, the leading cause of death worldwide. HDL particles are thought to mediate the uptake of peripheral cholesterol and, through exchange of core lipids with other lipoproteins or selective uptake by specific receptors, return this cholesterol to the liver for bile acid secretion or hormone synthesis in steroidogenic tissues. HDL particles also act on vascular processes by modulating vasomotor function, thrombosis, cell-adhesion molecule expression, platelet function, nitric oxide release, endothelial cell apoptosis and proliferation. Many of these effects involve signal transduction pathways and gene transcription. Several genetic disorders of HDLs have been characterized at the molecular level. The study of naturally occurring mutations has considerably enhanced understanding of the role of HDL particles. Some mutations causing HDL deficiency are associated with premature coronary artery disease, while others, paradoxically, may be associated with longevity. Modulation of HDL metabolism for therapeutic purposes must take into account, not only the cholesterol content of a particle but its lipid (especially phospholipid) composition, apolipoprotein content, size and charge. Current therapeutic strategies include the use of peroxisome proliferating activator receptor-alpha agonists (fibrates) that increase apolipoprotein AI production and increase lipoprotein lipase activity, statins that have a small effect on HDL-cholesterol but markedly reduce low-density lipoprotein-cholesterol, the cholesterol/HDL-cholesterol ratio and niacin that increases HDL-cholesterol. Potential therapeutic targets include inhibition of cholesteryl ester transfer protein, modulating the ATP-binding cassette A1 transporter, and decreasing HDL uptake by scavenger receptor-B1. Novel therapies include injection of purified apolipoprotien AI and short peptides taken orally, mimicking some of the biological effects of apolipoprotein AI.
Collapse
Affiliation(s)
- Michel Marcil
- McGill University Health Center, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, H3A 1A1 QC, Canada.
| | | | | | | |
Collapse
|
22
|
Abstract
There is a large body of evidence demonstrating an inverse correlation between circulating levels of high-density lipoprotein (HDL) cholesterol and cardiovascular disease risk. For every 1-mg/dL increase in HDL, it is estimated that the risk of cardiovascular events decreases by 2% to 3%. HDL is one of many factors that contribute to the regulation of the atherosclerotic process. HDL mediates reverse cholesterol transport and exhibits numerous beneficial properties, including antioxidant, antiinflammatory, and antithrombotic effects on the vasculature. Recent studies have expanded our understanding of the vasoprotective mechanisms of HDL to include enhanced nitric oxide production and improved endothelium-dependent relaxation. Progress has also been made in determining the molecular mechanisms that mediate reverse cholesterol transport. Recently published National Cholesterol Education Program Adult Treatment Panel guidelines have broadened the definition of low levels of HDL and encourage more aggressive screening and treatment of lipid abnormalities. Several therapeutic interventions can augment HDL concentrations, and there is increasing evidence that these interventions improve cardiovascular outcomes. Research focusing on defining the molecular roles of HDL will likely identify potential therapeutic targets for decreasing the incidence and progression of coronary heart disease. This review highlights the role of HDL in coronary heart disease, from basic mechanisms of action to recent clinical trial results.
Collapse
Affiliation(s)
- Christine E Young
- Department of Medicine/Division of Cardiology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
| | | | | |
Collapse
|
23
|
Abstract
Obesity is a growing health problem in the U.S. As a complex trait, obesity involves multiple genes and gene-gene and gene-environment interactions that contribute to its pathogenesis. Here we report significant linkage from a scan of a large sample segregating extreme obesity and normal weight. We have used 382 microsatellite markers in 1,297 individuals from 260 European-American families. We conducted nonparametric linkage (NPL) analyses for dichotomous BMI (using BMI >/=27, >/=30, >/=35, and >/=40 kg/m(2)) using Genehunter. We also analyzed quantitative traits (BMI, percentage of fat, and waist circumference) by the family regression method using Merlin_regress. We found evidence for linkage on chromosome 12 (125 cM, D12S2070, logarithm of odds [LOD] 3.79, P = 0.00001 for percentage of fat; LOD 2.98, P = 0.0001 for BMI; and LOD 2.86, P = 0.00014 for waist circumference) by family regression analyses. Adding three additional markers to the intervals flanking the chromosome 12 peak yielded an LOD score of 4.08 (P = 0.00001) for percentage of fat at 116 cM and LOD scores of 3.57 (P = 0.00003) and 3.05 (P = 0.00009) for BMI and waist circumference, respectively, at 125 cM. We also obtained other suggestive linkages on chromosomes 2, 3, 7, 8, 9, 12, 13, and 21. Our results suggest multiple loci that could influence obesity, particularly a locus in chromosome region 12q23-24.
Collapse
Affiliation(s)
- Wei-Dong Li
- Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | | | | |
Collapse
|
24
|
Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24:357-87. [PMID: 12788804 DOI: 10.1210/er.2001-0037] [Citation(s) in RCA: 313] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Because cholesterol is a precursor for the synthesis of steroid hormones, steroidogenic tissues have evolved multiple pathways to ensure adequate supplies of cholesterol. These include synthesis, storage as cholesteryl esters, and import from lipoproteins. In addition to endocytosis via members of the low-density lipoprotein receptor superfamily, steroidogenic cells acquire cholesterol from lipoproteins by selective lipid uptake. This pathway, which does not involve lysosomal degradation of the lipoprotein, is mediated by the scavenger receptor class B type I (SR-BI). SR-BI is highly expressed in steroidogenic cells, where its expression is regulated by various trophic hormones, as well as in the liver. Studies of genetically manipulated strains of mice have established that SR-BI plays a key role in regulating lipoprotein metabolism and cholesterol transport to steroidogenic tissues and to the liver for biliary secretion. In addition, analysis of SR-BI-deficient mice has shown that SR-BI expression is important for alpha-tocopherol and nitric oxide metabolism, as well as normal red blood cell maturation and female fertility. These mouse models have also revealed that SR-BI can protect against atherosclerosis. If SR-BI plays similar physiological and pathophysiological roles in humans, it may be an attractive target for therapeutic intervention in cardiovascular and reproductive diseases.
Collapse
Affiliation(s)
- Attilio Rigotti
- Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica, Santiago, Chile
| | | | | |
Collapse
|
25
|
Pérez-Martínez P, Ordovás JM, López-Miranda J, Gómez P, Marín C, Moreno J, Fuentes F, Fernández de la Puebla RA, Pérez-Jiménez F. Polymorphism exon 1 variant at the locus of the scavenger receptor class B type I gene: influence on plasma LDL cholesterol in healthy subjects during the consumption of diets with different fat contents. Am J Clin Nutr 2003; 77:809-13. [PMID: 12663276 DOI: 10.1093/ajcn/77.4.809] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The association between polymorphisms in the scavenger receptor class B type I (SRB-I) gene and variations in basal plasma concentrations of cholesterol in humans has recently been described. OBJECTIVE The objective of the study was to determine whether the exon 1 variant (G-->A) at the SRB-I gene is associated with the lipid response to the content and quality of dietary fat in healthy subjects. DESIGN We studied 97 healthy volunteers with exon 1 polymorphism [65 homozygous for allele 1 (1/1) and 32 heterozygous for allele 2 (1/2)]. Both groups consumed 3 diets lasting 4 wk each. The first was a saturated fatty acid (SFA)-rich diet (38% fat, 20% SFA), which was followed by a carbohydrate (Cho)-rich diet (30% fat, < 10% SFA, 55% carbohydrate) or a monounsaturated fatty acid (MUFA), olive oil-rich diet (38% fat, 22% MUFA) according to a randomized crossover design. At the end of each dietary period, plasma concentrations of triacylglycerol and of total, LDL, and HDL cholesterol were measured. RESULTS Carriers of the 1/2 genotype had a trend toward higher concentrations of LDL cholesterol (P < 0.11) after the SFA-rich diet than did those who were homozygous for 1/1. Carriers of the mutation showed a significantly greater (P = 0.007) decrease in LDL-cholesterol concentrations (-23%) in changing from an SFA-rich diet to a Cho-rich diet than did noncarriers of the mutation (-16%). CONCLUSION Carriers of the minority allele, 1/2, are more susceptible to the presence of SFA in the diet because of a greater increase in LDL cholesterol.
Collapse
Affiliation(s)
- Pablo Pérez-Martínez
- Unidad de Lipidos y Arteriosclerosis, Hospital Universitario Reina Sofia, Córdoba, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Sowden MP, Ballatori N, Jensen KLDM, Reed LH, Smith HC. The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. J Cell Sci 2002; 115:1027-39. [PMID: 11870221 DOI: 10.1242/jcs.115.5.1027] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Apolipoprotein B mRNA cytidine to uridine editing requires the assembly of a multiprotein editosome comprised minimally of the catalytic subunit,apolipoprotein B mRNA editing catalytic subunit 1 (APOBEC-1), and an RNA-binding protein, APOBEC-1 complementation factor (ACF). A rat homolog has been cloned with 93.5% identity to human ACF (huACF). Peptide-specific antibodies prepared against huACF immunoprecipitated a rat protein of similar mass as huACF bound to apolipoprotein B (apoB) RNA in UV cross-linking reactions, thereby providing evidence that the p66, mooring sequence-selective, RNA-binding protein identified previously in rat liver by UV cross-linking and implicated in editosome assembly is a functional homolog of huACF. The rat protein (p66/ACF) was distributed in both the nucleus and cytoplasm of rat primary hepatocytes. Within a thin section, a significant amount of total cellular p66/ACF was cytoplasmic, with a concentration at the outer surface of the endoplasmic reticulum. Native APOBEC-1 co-fractionated with p66/ACF in the cytoplasm as 60S complexes. In the nucleus, the biological site of apoB mRNA editing, native p66/ACF, was localized to heterochromatin and fractionated with APOBEC-1 as 27S editosomes. When apoB mRNA editing was stimulated in rat primary hepatocytes with ethanol or insulin, the abundance of p66/ACF in the nucleus markedly increased. It is proposed that the heterogeneity in size of complexes containing editing factors is functionally significant and reflects functionally engaged editosomes in the nucleus and an inactive cytoplasmic pool of factors.
Collapse
Affiliation(s)
- Mark P Sowden
- Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
| | | | | | | | | |
Collapse
|
27
|
Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 2002; 82:199-207; discussion 207-8. [PMID: 11911905 DOI: 10.1016/s0167-5273(01)00625-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Two major trials, the Bezafibrate Infarction Prevention Trial (BIP) and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) were conducted to clarify the contribution of correcting diminished high density lipoprotein (HDL) (and lowering triglyceride, TG) levels to the risk of cardiovascular events in patients with coronary heart disease (CHD). In BIP, bezafibrate did not significantly reduce the risk of CHD. In contrast, in VA-HIT, gemfibrozil significantly reduced the risk of CHD (22% reduction in primary end point, P=0.006). These trials differ in several respects making direct comparisons difficult. For example, the placebo arm in VA-HIT had a greater prevalence of primary events than that in BIP (22 vs. 15%). The baseline mean LDL value in BIP was also higher compared to that in VA-HIT (148 vs. 112 mg/dl; 3.82 vs. 2.89 mmol/l). Other trials (e.g., AFCAPS and LIPID) showed that patients with LDL values similar to those in BIP benefited significantly from treatment with statins. Therefore, the BIP population may have been more effectively treated with a statin. In contrast, in VA-HIT the LDL level was close to those recommended in the USA and the UK for secondary prevention (100 and 115 mg/dl; 2.6 and 3.0 mmol/l, respectively). Guidelines emphasise that the LDL level is the main treatment target. However, BIP and VA-HIT suggest that correcting HDL and TG levels may be beneficial especially when the LDL level has reached the target value. We may have become too focused on LDL levels and the use of statins.
Collapse
Affiliation(s)
- E Rizos
- Department of Clinical Biochemistry (Cardiovascular Disease Prevention Service), Royal Free & University College Medical School, University College (University of London), Royal Free Campus, Pond Street, London NW3 2QG, UK
| | | |
Collapse
|
28
|
Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J Lipid Res 2001. [DOI: 10.1016/s0022-2275(20)31676-x] [Citation(s) in RCA: 230] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
29
|
Trigatti BL, Rigotti A, Braun A. Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. BIOCHIMICA ET BIOPHYSICA ACTA 2000; 1529:276-86. [PMID: 11111095 DOI: 10.1016/s1388-1981(00)00154-2] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
High-density lipoproteins (HDL) play an important role in protection against atherosclerosis by mediating reverse cholesterol transport - the transport of excess cholesterol from peripheral tissues to the liver for disposal. SR-BI is a cell surface receptor for HDL and other lipoproteins (LDL and VLDL) and mediates the selective uptake of lipoprotein cholesterol by cells. Overexpression or genetic ablation of SR-BI in mice revealed that it plays an important role in HDL metabolism and reverse cholesterol transport and protects against atherosclerosis in mouse models of the disease. If it plays a similar role in humans then it may be an attractive target for therapeutic intervention. We will review some of the recent advances in the understanding of SR-BI's physiological role and cellular function in lipoprotein metabolism.
Collapse
Affiliation(s)
- B L Trigatti
- Biology Department, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
| | | | | |
Collapse
|
30
|
Abumrad NA, Sfeir Z, Connelly MA, Coburn C. Lipid transporters: membrane transport systems for cholesterol and fatty acids. Curr Opin Clin Nutr Metab Care 2000; 3:255-62. [PMID: 10929670 DOI: 10.1097/00075197-200007000-00003] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Lipophilic molecules can passively diffuse across cell membranes, a process that is driven by the concentration gradient, by availability of acceptors to facilitate desorption from the bilayer, and by cellular metabolism. However, evidence has accumulated that supports the existence of specialized, protein-facilitated membrane transport systems for many lipophilic molecules. This has generated considerable debate regarding why such systems need to exist. The present review summarizes recent developments related to the membrane transport systems for cholesterol and fatty acids, which have been shown to involve structurally related proteins. General similarities of the cholesterol and fatty acid systems to other lipid transport systems (briefly discussed in the Introduction section) are highlighted in the Conclusion section. The overall aim of the present review is to illustrate why lipid transporters are needed in vivo, and how they accomplish specific functions that can not be met by lipid diffusion alone.
Collapse
Affiliation(s)
- N A Abumrad
- Department of Physiology and Biophysics, State University of New York at Stony Brook, 11794-8661, USA.
| | | | | | | |
Collapse
|
31
|
Abstract
The HDL receptor scavenger receptor class B type I (SR-BI), which mediates selective HDL cholesterol uptake, plays a role in murine HDL metabolism, reverse cholesterol transport and whole-body cholesterol homeostasis. SR-BI is found in the liver, where its expression is regulated by estrogen, dietary cholesterol and fat, and controls murine plasma HDL cholesterol levels and bile cholesterol secretion. SR-BI is also highly expressed in rodent steroidogenic cells, where it facilitates cholesterol uptake for storage or steroid hormone synthesis and where its expression is regulated by trophic hormones. The detailed mechanism(s) underlying SR-BI-mediated selective cholesterol uptake have not yet been elucidated. Further analysis of the molecular and cellular bases of SR-BI regulation and function should provide new insights into the physiology and pathophysiology of cholesterol metabolism.
Collapse
Affiliation(s)
- B Trigatti
- Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA
| | | | | |
Collapse
|